Xembify not checked

Grifols Therapeutics LLC · IGSC 20%

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%)”In the company’s words, NCT07540221 on ClinicalTrials.gov
Tested for
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Main trialPhase 3
“The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP. Participants with CIDP will first have up to 28 days of screening to make sure they can join the study. Those who qualify will then start a 19-week treatment period with Gamunex-C. During this period, they will receive Gamunex-C through a vein once every 3 weeks, for a total of 7 doses. Approximately, one week after their last Gamunex-C dose, they will…”In the company’s words, NCT07540221 on ClinicalTrials.gov
Other names
IGSC 20%

Other drugs for CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

All 14 drugs for CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2027 A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Phase 3Recruiting Aug 2029 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Phase 4Completed 18 Jul 2022 A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Xembify

Following is part of Solo: you see every change to Xembify the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in